Smith & Nephew (SN) CMD 2025 summary

Strategic Vision and Future Growth

• Launched the RISE strategy, targeting 6-7% organic revenue CAGR and 9-10% trading profit CAGR through 2028, with a focus on innovation, operational efficiency, and disciplined capital allocation.

• Aims to reach 20 million patients annually by 2028, up from 15 million, through differentiated product launches and expanded global reach.

• Key growth drivers include Sports Medicine, Wound Management, and ENT, with Orthopaedics expected to return to market growth and drive margin expansion.

• Strategic investments will prioritize high-return segments, especially in Sports and Wound, with targeted M&A to support portfolio priorities.

• Portfolio rationalisation and operational improvements, including a 54% SKU reduction in Orthopaedics and $500 million inventory reduction, will enhance efficiency and capital returns.

Financial Guidance and Performance

• 2028 targets include over $1 billion in free cash flow and 12-13% ROIC, with Orthopaedics margin expected to exceed 20% by 2030.

• Achieved a 14-fold increase in free cash flow since 2022 and expanded trading margin by over 200 bps despite macro headwinds.

• 2025 outlook: around 5% revenue growth, at least 19.5% trading margin, and ~$800 million free cash flow; 2026 guidance: ~6% revenue growth, profit growth ahead of revenue, ~$800 million FCF, ROIC above 10%.

• Operational savings of $325-$375 million are on track, with further cost benefits expected from manufacturing, procurement, and zero-based budgeting.

• Capital allocation will focus on organic and inorganic growth, with leverage allowed to rise for strategic acquisitions and surplus capital returned to shareholders.

Innovation and Product Pipeline

• Over $1.2 billion invested in R&D (2021-2024), supporting over 75 product launches in five years and two scalable innovation platforms: M.Tech (AI, robotics, sensors) and biologics.

• Major upcoming launches include the LANDMARK Knee, CORI XT robotics, TESSA spatial surgery platform, and next-gen LEAF sensor.

• Biologics platform leverages products like REGENETEN, Agili-C, and SANTYL, focusing on disease modification, tissue optimization, and accelerated healing.

• Clinical evidence and market access initiatives underpin adoption, with recent wins such as new CPT codes for Agili-C and national payment rates for TULA.

• Innovation is driven by business unit-led roadmaps and cross-functional centers of excellence, ensuring both incremental and transformative advances.